Seniors experiencing memory problems and cognitive decline now have access to a new diagnostic blood test to detect Alzheimer’s disease. Labcorp this week unveiled the first Food and Drug ...

Labcorp Holdings (LH) experienced a 10% price increase in the past month, which aligns with its recent strategic advancements including the launch of Lumipulse® pTau-217/Beta Amyloid 42 Ratio, marking ...

LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...

Prenatal exposure to chlorpyrifos -- mostly attributable to indoor residential spraying for pests, prevalent in inner-city ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...